Method of providing pirfenidone therapy to a patient
View Patent ↗The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.
1. A method of providing pirfenidone therapy to a patient for the treatment of idiopathic pulmonary fibrosis in an initial dose escalation regimen, comprising:
providing pirfenidone to a patient at a first oral daily dosage of 801 mg as one capsule comprising 267-mg of pirfenidone three times a day for days one to seven of the dose escalation regimen;
providing a second oral daily dosage of 1602 mg as two capsules comprising 267-mg of pirfenidone three times a day for days eight to fourteen of the dose escalation regimen;
providing a third oral daily dosage of 2403 mg as three capsules comprising 267-mg of pirfenidone three times a day for at least day fifteen of the dose escalation regimen; and
instructing said patient to take said dosages with food,
wherein the patient is provided pirfenidone for the treatment of idiopathic pulmonary fibrosis.
2. The method of claim 1 wherein the initial dose escalation regimen reduces the incidence of photosensitivity reaction adverse events.
3. The method of claim 2 , wherein the incidence of photosensitivity reaction adverse events is about 12%.
4. A method of reducing the incidence of photosensitivity reaction adverse events in a patient receiving pirfenidone therapy for the treatment of idiopathic pulmonary fibrosis, comprising use of an initial dose escalation regimen comprising the steps of:
providing pirfenidone to the patient at a first oral daily dosage of 801 mg as one capsule comprising 267-mg of pirfenidone three times a day for days one to seven of the dose escalation regimen;
providing a second oral daily dosage of 1602 mg as two capsules comprising 267-mg of pirfenidone three times a day for days eight to fourteen of the dose escalation regimen;
providing a third oral daily dosage of 2403 mg as three capsules comprising 267-mg of pirfenidone three times a day for at least day fifteen of the dose escalation regimen; and
instructing said patient to take said dosages with food.
5. The method of claim 4 , wherein the incidence of photosensitivity reaction adverse events is about 12%.
6. In a method of treating a patient with pirfenidone for idiopathic pulmonary fibrosis, the improvement comprising:
reducing the incidence of photosensitivity reaction adverse events in the patient receiving pirfenidone therapy by use of an initial dose escalation regimen comprising
providing pirfenidone to a patient at a first oral daily dosage of 801 mg as one capsule comprising 267-mg of pirfenidone three times a day for days one to seven of the dose escalation regimen;
providing a second oral daily dosage of 1602 mg as two capsules comprising 267-mg of pirfenidone three times a day for days eight to fourteen of the dose escalation regimen;
providing a third oral daily dosage of 2403 mg as three capsules comprising 267-mg of pirfenidone three times a day for at least day fifteen of the dose escalation regimen; and
instructing said patient to take said dosages with food.
7. The method of claim 6 , comprising reducing the incidence of photosensitivity reaction adverse events to about 12%.